Patric Nelson
Ionis Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Pharmaceutical Economics and Policy, Diabetes Treatment and Management, Diabetes Management and Research, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia(2014)493 cited
- → Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia(2013)216 cited
- → Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes(2009)132 cited
- → Exenatide Improves Glycemic Control and Reduces Body Weight in Subjects with Type 2 Diabetes: A Dose-Ranging Study(2005)105 cited
- → Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome(2016)64 cited
- → The Incretin Mimetic Exenatide as a Monotherapy in Patients with Type 2 Diabetes(2007)46 cited
- → Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy(2014)15 cited
- → PM385 Safety, Tolerability, And Efficacy Of Long-Term Administration Of Monthly AMG 145 In Subjects With Heterozygous Familial Hypercholesterolemia(2014)2 cited
- → Effects of Long-Term, Monthly Administration of the PCSK9 Inhibitor Evolocumab in Patients with Dysglycemia or Metabolic Syndrome(2014)2 cited
- → Platelet‐activating factor increases nitric oxide production, but does not induce nitric oxide synthetase expression, in human fetal membranes in culture(2000)